Neurology

Soy isoflavones decrease frequency and duration of migraine attacks in women

Natalia Reoutova, 3 days ago

A randomized controlled trial of reproductive-age women prone to migraines has shown soy isoflavones supplementation to be effective at reducing the frequency and duration of migraine attacks.

Bilateral movement computer games improve upper limb recovery in stroke survivors

Natalia Reoutova, 3 days ago

A randomized controlled trial conducted by researchers from Hong Kong Metropolitan University, the Hong Kong Polytechnic University and the Chinese University of Hong Kong found greater improvements in upper limb sensorimotor functions among subacute stroke survivors who engaged in bilateral movement-based computer games (BMCG) vs conventional rehabilitation (CR) alone.

Conjugated equine estrogen plus estradiol tied to increased risk of haemorrhagic stroke

4 days ago

Menopausal hormone therapy with conjugated equine estrogen appears to confer a heightened risk of developing haemorrhagic stroke among postmenopausal women as compared with the use of estradiol, as reported in a retrospective cohort study.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

MS patients on certain DMTs may have limited protection from COVID-19 vax

Roshini Claire Anthony, 30 May 2022

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

Keto diet: Is there good evidence in MS?

Elvira Manzano, 23 May 2022

A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.

Sustained benefits with ocrelizumab in relapsing-remitting MS

Roshini Claire Anthony, 19 May 2022

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia

Elaine Soliven, 19 May 2022

Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.

How does IV edaravone fare for ALS in the real world?

Audrey Abella, 10 May 2022

Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.